uniQure to Participate in Multiple Upcoming Industry Conferences in November
November 01 2019 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in November:
- Huntington Study Group
2019: Navigating Huntington’s Disease, November 7 – 9, Sacramento,
California.° Eileen Sawyer, VP of Global Medical
Affairs, will give an oral presentation on the study design of our
Phase I/II clinical trial of AMT-130 for Huntington’s disease on
November 7, and will be participating in the “Research Roundup”
roundtable on November 8, at 5:30 p.m. PT.
- Credit Suisse 28th Annual
Healthcare Conference, November 11 – 13, Scottsdale,
Arizona.° Members of uniQure’s management team will
attend and participate in one-on-one investor meetings throughout
the day on Tuesday, November 12.
- 10th Annual World Orphan
Drug Congress, November 11 – 14, Barcelona,
Spain.° Sander van Deventer, EVP Research &
Product Development will participate in the panel discussion
“Executive Insights: What technologies need to be unlocked?
Discussing all the scientific aspects that are impacting the
reality of gene therapy” on Wednesday November 13 at 9:55 a.m.
CET.° In addition, he will participate in the
panel discussion “European Investment Landscape for Cell & Gene
Therapy” on Thursday November 14, at 2:40 p.m. CET.
- Barclays Gene Editing &
Gene Therapy Summit, November 13, New York
City.° Matt Kapusta, chief executive officer will
present a corporate update on Wednesday November 13, at 10:15 a.m.
ET. Members of uniQure’s management team will participate in
one-on-one investor meetings throughout the day on Wednesday,
November 13.
- World Federation of
Hemophilia Global Forum, November 13 – 14, Montreal,
Canada° Eileen Sawyer will give an oral presentation
on “Interim Results from a Phase 2b trial of Etranacogene
Dezaparvovec (AMT-061: AAV5-Padua hFIX variant), an Enhanced Vector
for Gene Transfer in Adults with Severe or Moderate-Severe
Hemophilia B”, on Thursday November 14, at 9:00 a.m. ET.
- Stifel 2019 Healthcare
Conference, November 19 – 20, New York City.° Matt
Kapusta will present a corporate update on Tuesday November 19 at
9:30 a.m. ET. The live webcast of the corporate update can be
accessed through the link displayed in the Investor section of the
uniQure website. The webcast replay will be available for at least
72 hours following the live event.
- 29th Annual Network for
European CNS Transplantation and Restoration (NECTAR) Meeting,
November 28 – 29, Cardiff, United Kingdom.° Pavlina
Konstantinova, VP new therapeutic target development at uniQure,
will be presenting “Development of a microRNA-based Gene Therapy
for Huntington’s Disease “, on Thursday, November 28 at 10:30 a.m.
GMT.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
hemophilia A, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure Contacts: |
|
|
|
|
FOR INVESTORS: |
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024